Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 19/20 | 1.00 |
| ▸ | HTR1A | P08908 | 18/20 | 1.00 |
| ▸ | HTR1D | P28221 | 16/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628236 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907348 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907353 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL2335932 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL17402421 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL8624139 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL17402426 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907322 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907325 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL21523192 | 0.99 | MAPT (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063492-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-0666847-B1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMA (CA) | 1998-06-17 | — | — | EP | disclosed |
| US-5496957-A | 5-HYDOXYTRYPTAMINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-05 | — | — | US | disclosed |
| EP-0666847-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | Allelix Biopharmaceuticals Inc. (CA) | 1995-08-16 | — | — | EP | disclosed |
| WO-1995006638-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | HTR1B 435/4885HTR1A 152/4885HTR1D 1044/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | HTR1B 435/4885HTR1A 152/4885HTR1D 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.